Icomas

Methane, Acetylene, Carbon Monoxide, the active ingredient in Icomas, is a medical gas presented as an inhalation gas for inhalation use. It is investigated for respiratory therapy applications, primarily in controlled clinical settings and research environments.

GNH USA supplies Icomas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Icomas is a medical gas mixture; at present it has no approved therapeutic indications.

- Investigational use: evaluated in clinical trials for potential respiratory support. - Research application: employed in studies of gas physiology and metabolic effects. - Educational demonstration: used to illustrate properties of combustible inhalation gases.

Icomas may cause a range of adverse reactions when inhaled.

Common Side Effects: - Headache: mild to moderate discomfort. - Dizziness: sensation of light‑headedness. - Nausea: feeling of queasiness. - Cough: irritation of the airway. - Light‑headedness: transient loss of balance. - Irritation: mild throat or nasal irritation.

Serious or Rare Side Effects: - Carbon monoxide poisoning: severe hypoxia and neurological impairment. - Loss of consciousness: sudden fainting episodes. - Arrhythmia: irregular heart rhythm. - Pulmonary edema: fluid accumulation in lungs. - Seizures: convulsive episodes. - Severe hypoxia: critically low oxygen levels.

Safe handling of Icomas requires specific precautions.

- Assess patient suitability: evaluate respiratory status before administration. - Monitor oxygen saturation: ensure adequate oxygenation throughout use. - Avoid use in confined spaces: prevent accumulation of combustible gases. - Use compatible delivery system: ensure equipment is rated for combustible gases. - Educate staff: train personnel on safe handling and emergency procedures. - Store at ambient temperature: keep cylinders in a well‑ventilated, cool, dry area away from ignition sources.

Icomas may interact with other inhaled agents and therapies.

Major Interactions (Avoid): - Oxygen therapy: high concentrations may displace oxygen, causing hypoxia. - Nitrous oxide: combined use can increase risk of respiratory depression. - Anesthetic gases: additive central nervous system depression.

Moderate Interactions (Monitor Closely): - Bronchodilators: may alter respiratory response. - Corticosteroids: monitor respiratory status despite no direct chemical interaction. - Smoking: increased risk of carbon monoxide toxicity.